Fulgent Genetics, Inc.

As of June 30, 2026, Fulgent Genetics, Inc. carries a market capitalization of 9.62B, placing it among publicly traded companies globally. Its enterprise value stands at 5.19B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Fulgent Genetics, Inc.'s next confirmed earnings release is scheduled for November 5, 2026.

As of June 30, 2026, Fulgent Genetics, Inc. has 27.52M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 1.86, and the price-to-book ratio stands at 0.55.

These figures are as of June 30, 2026. The EV/Sales ratio of 0.92 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 5.19B versus a market cap of 9.62B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Fulgent Genetics, Inc. maintains a current ratio of 6.34, meaning it holds 6.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 0.95, indicating moderate leverage, while an interest coverage ratio of -803.81 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Fulgent Genetics, Inc. posted a negative return on equity (ROE) of -7.97, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -7.37, reflecting losses generated across the asset base. The company generates approximately 4.24M in revenue per employee across its workforce of 1,336.25, a quick read on workforce productivity versus industry peers. Inventory turnover of 20.21 indicates how many times Fulgent Genetics, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Fulgent Genetics, Inc. recorded an income tax benefit of -121.99M rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -1.62B and -1.47B in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 16, 2026, Fulgent Genetics, Inc.'s stock has declined approximately 14.77% over the past 52 weeks.

Over the twelve months ended June 30, 2026, Fulgent Genetics, Inc. generated 5.66B in revenue and converted that into -1.47B in net income, yielding earnings per share of -49.52. EBITDA reached -1.69B, while operating income came in at -2.10B.

As of June 30, 2026, Fulgent Genetics, Inc. holds 4.49B in cash and equivalents against 164.62M in total debt, resulting in a net debt position of -425.38M. Total book value stands at 17.50B, with working capital of 6.69B providing operational flexibility.

Fulgent Genetics, Inc. produced -1.46B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -351.00M in capital expenditures, free cash flow totaled -1.81B - equivalent to -60.14 per share.

Over the twelve months ended June 30, 2026, Fulgent Genetics, Inc. posted a gross margin of 35.58, reflecting its pricing power and cost economics. The operating margin of -37.08 and net profit margin of -26.05 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -17.21: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield reaches 12.72, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Fulgent Genetics, Inc. shareholders.

As of June 30, 2026, Fulgent Genetics, Inc. has an Altman Z-Score of 4.73, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.